Minimal Residual Disease Speeds Up Myeloma Drug Approvals
Bristol Myers Squibb’s Nathan Pennell says MRD is cutting regulatory wait times for multiple myeloma drugs, but doctors still rely on standard clinical monitoring.
Clinical Endpoints 2 articles
Clinical Endpoints examines the outcome measures used to determine whether a trial has met its objectives. Primary and secondary endpoints, surrogate measures, patient-reported outcomes, time-to-event metrics and composite endpoints are assessed for validity, interpretability and regulatory relevance. The category differs from Trial Design because the endpoint itself is the object of analysis, and from Clinical Trial Statistics because the focus is what is measured rather than how treatment effects are estimated.
Rosera advances NLRP3 inhibitor ravnoflast to Phase 3 in cardiovascular disease
Rosera is staking its future on ravnoflast, an engineered NLRP3 inhibitor now heading into a pivotal Phase 3 trial for peripheral artery disease. The company aims to make tissue-level inflammation a treatable target in cardiovascular care.